Home › Research › Treatments
Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial
Lovró Z, Sandberg A, Zetterberg H, Pierrou S, Parkkola R, Sjögren N, Scheinin M, Rinne JO.. Alzheimer's research & therapy, 2026-05-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results ALZ-101 was not associated with any clear safety signals, and no serious adverse drug reactions were observed. No statistically significant between‑group differences were detected for pre‑specified CSF biomarkers or cognitive and functional outcomes versus placebo in the randomised phase. Over longer follow‑up in Part B, participants initially randomised to ALZ‑101 showed numerically smaller increases in CSF neurofilament light chain (NfL) and tau and a flatter ADCOMS trajectory than those initially on placebo, but these differences were not statistically significant. Conclusion In this small Phase 1 study in early AD, ALZ‑101 was not associated with clear safety signals and elicited strong, durable Aβ‑specific antibody responses. These results support further evaluation of ALZ‑101 in larger, adequately powered trials.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lovró, Z., Sandberg, A., Zetterberg, H., Pierrou, S., Parkkola, R., Sjögren, N., et al. (2026). Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-026-02082-9
Vancouver
Lovró Z, Sandberg A, Zetterberg H, Pierrou S, Parkkola R, Sjögren N, et al. Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial. Alzheimer's research & therapy. 2026. doi:10.1186/s13195-026-02082-9. PMID: 42157213.
BibTeX
@article{lovro2026-42157213,
author = {Lovró, Z. and Sandberg, A. and Zetterberg, H. and Pierrou, S. and Parkkola, R. and Sjögren, N. and Scheinin, M. and Rinne, J. O.},
title = {{Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial}},
journal = {Alzheimer's research \& therapy},
year = {2026},
doi = {10.1186/s13195-026-02082-9},
pmid = {42157213},
url = {https://doi.org/10.1186/s13195-026-02082-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results ALZ-101 was not associated with any clear safety signals, and no serious adverse drug reactions were observed.
- No statistically significant between‑group differences were detected for pre‑specified CSF biomarkers or cognitive and functional outcomes versus placebo in the randomised phase.
- Over longer follow‑up in Part B, participants initially randomised to ALZ‑101 showed numerically smaller increases in CSF neurofilament light chain (NfL) and tau and a flatter ADCOMS trajectory than those initially on placebo, but these differences were not statistically significant.
- Conclusion In this small Phase 1 study in early AD, ALZ‑101 was not associated with clear safety signals and elicited strong, durable Aβ‑specific antibody responses.
- These results support further evaluation of ALZ‑101 in larger, adequately powered trials.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Evidence strengthHigh
How this study scored 79/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 46 of the 58 points we could judge it on, which is 79 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42157213) |
| Free to read | 2 / 2 | Free to read |
| Points | 46 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 46 of the 58 points we could judge it on is 79 out of 100. |
| Total | 79 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “randomised-controlled”
3 studies in the library carry the topic tag “randomised-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.